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Abstract
General anesthesia accompanied by surgical stress is considered to suppress immunity, 
presumably by directly affecting the immune system or activating the hypothalamic-pituitary-adrenal 
axis and the sympathetic nervous system.  Along with stress such as surgery, blood transfusion, 
hypothermia, hyperglycemia and postoperative pain, anesthetics per se are associated with 
suppressed immunity during perioperative periods because every anesthetic has direct suppressive 
effects on cellular and neurohumoral immunity through influence upon the functions of 
immunocompetent cells and inflammatory mediator gene expression and secretion.  Particularly in 
cancer patients, immunosuppression attributable to anesthetics, such as dysfunctions of natural killer 
cells and lymphocytes, might accelerate the growth and metastases of residual malignant cells, 
thereby worsening prognoses.  Alternatively, anti-inflammatory effects of anesthetics might be 
beneficial in distinct situations involving ischemia and reperfusion injury or the systemic 
inflammatory response syndrome (SIRS).  Regarding the respective long-term mortalities, 
morbidities, and the optimal prognoses, clinical anesthesiologists should select anesthetics and 
choose anesthetic methods with careful consideration of the clinical situation and immunity status of 
critically ill patients.
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Introduction
The possible effects of anesthesia on the immune system have been discussed from the early 
20th century.  Studies reported by Graham in 1911 [1] and Gaylord in 1916 [2] respectively describe 
the influence of ether anesthesia on bacteriolysis and phagocytosis in human, and the effects of 
anesthetics on tumor growth in an animal model.  During recent decades, rapid development has 
occurred in the fields of immunology and anesthesia.  In the early 21st century, anesthesiologists 
acknowledged that dysregulation or suppression of the immune system during the perioperative 
period provokes postoperative complications, e.g. wound healing disturbances and infections leading 
to sepsis followed by multiple organ failure and death [3].  Particularly in cancer patients, 
immunosuppression after surgery accelerates the development of residual cancer cells and promotes 
the establishment of new metastases [4].  Immunological effects affect the long-term outcomes of 
patients after surgery. Therefore, awareness of immunological properties in the surgical area is 
helpful for daily anesthetic management.
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Factors and possible mechanisms of immunosuppression during the perioperative period –
implications for long-term outcomes of immunocompromised patients
The main causes of immunocompromised responses in surgical patients are well known to be 
related to the neuroendocrine stress through activation of the autonomic nervous system and the 
hypothalamic-pituitary-adrenal axis (HPA)(Fig. 1) [5–6].  Apparently, many immune changes 
occurring in surgical patients primarily result from surgical trauma and neuroendocrine responses.  
Surgical-stress-induced releases of hormones such as catecholamines (norepinephrine and 
epinephrine), adrenocorticotropin hormone (ACTH), and cortisol via the autonomic nervous system 
and the HPA mediate inhibitory effects on immune functions because monocytes and macrophages 
and T cells have both -adrenoreceptors and glucocorticoid receptors, which promote cellular 
signaling to inhibit the production of representative helper T cell 1 (Th1) cytokines such as IL-12 
and interferon (IFN)-and to produce Th2 cytokines, so-called anti-inflammatory cytokines such as 
interleukin (IL)-4 and IL-10 [7].  Although these Th2 cytokines act intrinsically to limit the 
exaggerated inflammatory responses induced by surgical trauma, excessive or uncontrolled secretion 
of Th2 cytokines engenders immunosuppression. Pro-inflammatory cytokines such as IL-1, IL-6, 
and tumor necrosis factor (TNF)-from monocytes and macrophages and lymphocytes activated by 
surgical stress can stimulate the HPA [5].  Therefore, the neuroendocrine system, the 
pro-inflammatory cytokines and anti-inflammatory cytokines, synergistically augment their 
suppressive effects in the perioperative immune system. Indeed, this immunosuppressive network by 
the activated neuroendocrine system and hypercytokinemia during the perioperative period might 
adversely affect long-term clinical outcomes.  For example, Younes et al. demonstrated in their 
high-impact study that the number of hypotensive episodes during an operation was associated with 
a shorter disease-free interval after liver resection for metastatic colorectal carcinoma as the single 
most significant risk factor [8].  The precise mechanism by which the intraoperative hypotension 
accelerated the recurrence and/or metastases of malignant tumor after surgery remains unclear, but 
the activation of the neuroendocrine system induced by intraoperative hypotension might engender 
inhibitory effects on anti-tumor immunity, especially on natural killer cells and lymphocyte functions 
in the patients.
In addition to the management of intraoperative blood pressure, blood transfusion [8–10], 
hyperglycemia [11–12], hypothermia [13–15], and postoperative pain [16–18], which are managed 
by anesthesiologists during operations, cause perioperative immunosuppression (Fig. 2).  
Immunosuppression by hypothermia and postoperative pain probably are mediated through 
activation of the neuroendocrine system because perioperative hypothermia impairs the oxidative 
killing function of neutrophils by triggering thermoregulatory vasoconstriction under the control of 
the autonomic nervous system [5]; also, postoperative pain activates HPA [17,19].  Hyperglycemia 
during perioperative periods increases the risk of bacterial infections because of the glycosylation of 
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circulating immunoglobulin [20] and the impaired phagocytic capacity of neutrophils, of which 
respiratory burst (i.e. explosive secretion of reactive oxygen species) is dependent on nicotinamide 
adenine dinucleotide phosphate hydroxide (NADPH) from the hexose monophosphate metabolism.  
Particularly for diabetes, NADPH is less available for neutrophil functions because the polyol 
pathway, which is a great consumer of NADPH, is activated to reduce excess glucose into sorbitol 
[21, 22].  The mechanism underlying the immunosuppression associated with allogenic blood 
transfusion remains elusive.  It was recently suggested that allogenic blood transfusion probably 
promotes host immune cells to produce immunosuppressive Th2 cytokines such as IL-10 and IL-4 
[23, 24].
However, even when the anesthetic technique and the surgery are managed adequately, certain 
patients undergoing surgery for the malignant tumors later succumb to tumor progression with 
multiple metastases, resulting in death.  This clinical situation in cancer patients following surgery 
is now thought to be mediated in part by direct immunosuppressive effects of anesthetics and 
analgesic agents. Recently, along with immune suppression caused by surgical stress, numerous 
studies have shown that anesthetics and analgesic agents commonly used in surgery and in intensive 
care might directly affect the functions of immune-competent cells.  In comparison to surgical 
stress, anesthetics probably have a minor effect on the immune system in patients undergoing 
surgery because surgery by itself is reported to cause a 3–4-fold increase in retention of tumor 
metastases when compared to groups in which anesthesia was combined [4].  An 
immunosuppressive effect of approximately 20% normally might not have greater consequences for 
a patient.  However, the patient is already compromised, e.g., because of aging, tumor burden, 
diabetes mellitus and malnutrition, immunosuppressive effects of anesthetics might play a salient 
role in postoperative morbidity and mortality [3].  On the other hand, immunosuppressive effects of 
anesthetics, which lead to anti-inflammatory responses, might be therapeutically beneficial in 
distinct situations such as ischemia and reperfusion injury or the systemic inflammatory response 
syndrome [25].  Therefore, anesthetics impart not only adverse effects but also beneficial effects on 
the perioperative immune system.  Investigations of the immune effects of anesthetics have been 
derived mostly from in vitro studies because clinical human studies are more complex in their 
findings, involving the type of surgery procedure, length of surgery, and patients’ complications.  
Although it is difficult to distinguish the relative contributions of surgical stress, anesthetics, and 
analgesic agents to a patient’s immune system, anesthesiologists must not ignore the 
immunosuppressive effects of anesthetic drugs on perioperative immunity because modern 
anesthesia now makes it possible to anesthetize immunocompromised patients.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
6
Overview of the immune system
1) Innate and acquired immunity
The Latin term immunis, meaning “exempt”, gave rise to the English word immunity.  The 
primary purpose of the immunity is to distinguish “self” from “nonself” and to clear “nonself” 
antigens from the body.  The two major components of immune response are non-specific innate 
immunity and specific acquired immunity.  Innate immunity is the first line defense against 
“non-self” invaders.  Innate immunity response is rapid, non-specific for the antigen, and requires 
no prior exposure to the antigen target to activate nonspecific immune system components.  Innate 
immune responses are mediated by natural killer (NK) cells and phagocytic cells such as monocytes, 
macrophages and polymorphonuclear neutrophils, which use primitive non-specific recognition 
systems to bind micro-organisms, then neutralize and destroy them [26].  In addition, monocytes 
and macrophages and dendritic cells play an important role as ‘professional’ antigen-presenting cells 
(APC)  to present the processed exogenous antigen in the groove of major histocompatibility 
complex (MHC) class II to helper T cells [27].
Acquired immunity is more specialized than innate immunity. It supplements the protection 
provided by innate immunity.  Acquired immunity came into play late in evolutionary terms: it is 
present only in vertebrates.  The initial contact with the foreign antigen triggers a chain of events 
that leads to activation of lymphocytes and the synthesis of proteins such as cytokines and antibodies.  
Acquired immunity is classified into humoral or cell-mediated immunity.  The humoral immunity is 
mediated by B cells, which produce antibody.  Other cells, T cells, are responsible for cell-mediated 
immunity and recognize an antigen only in the presence of MHC using the antigen-specific T cell 
receptors [28].  Actually, T cells comprise helper T cells (Th cells) and cytotoxic T cells (Tc cells).  
The particular type of Th cell is determined by the differentiation of precursor helper T cells (Th0) 
into Th1 or Th2 cells.  The Th1 cells produce IFN-and favor cell-mediated immune responses.  
The Th2 cells produce IL-4 and/or IL-10 and favor humoral immunity in the control of antibody 
production, leading to the suppression of cell-mediated immune responses, i.e. immunosuppression.  
For that reason, IL-4 and IL-10 are also called anti-inflammatory cytokines.  The Th1 responses are 
considered most beneficial in terms of an appropriate and effective response to trauma and infection 
[29–30].  The Tc cells recognize and destroy tumor cells and virus-infected cells.
2) The roles of NK cells in anti-tumor immunity
Especially useful in the early phases of host immune responses, NK cells are a distinct 
subpopulation of lymphoid lineage that can “naturally” kill certain tumor cells and virus-infected 
cells without prior sensitization or MHC restriction [31].  Considered as the third major 
lymphocytes population, NK cells account for approximately 5%–15% of peripheral lymphocytes in 
human.  It is common sense among tumor immunologists that NK cells, Tc cells and Th1 cells play 
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a crucial role for powerful elimination of tumor cells [32].  Particularly, NK cells function not only 
as a surveillant in the early stage of tumor development, including metastasis, and function through 
their capacity of killing activity; they also function as a helper in the priming process of APC, 
tumor-specific Tc cells, and Th1 cells by producing IFN-(Fig. 3)[33–36]Anti-tumor-specific Tc 
cells are considered to be the final and most important effectors against tumors. Therefore, NK cells 
are the main effectors responsible for the early anti-tumor defense [37].  Anti-inflammatory 
cytokines, IL-4 and IL-10; i.e., Th2 cytokines, are known to depress NK cell activities [38–39].  
This fact implies that anti-inflammatory cytokines produced by immune cells through activation of 
neuroendocrine system or blood transfusion play a potent role in suppressed NK-cell-mediated 
tumor immunity.  Therefore, a surgically mediated decrease in NK cell functions has been 
implicated as the major contributing factor associated with an increase in tumor metastases and 
recurrence.  Indeed, Ben-Eliyahu et al. have shown in an animal study that metastatic colonization 
of a lung tumor after surgery sensitively reflects in vivo activity levels of NK cell function [40].
3) Neutrophils and ischemia-reperfusion injury
Neutrophils are present in much larger numbers than any other inflammatory cell in circulation 
or in tissue.  Neutrophils are viewed as phagocytes that rapidly accumulate at the site of infection or 
tissue damage; they serve a pivotal role in the antimicrobial immunity at the early stage of infection 
by ingesting and killing invading microorganisms [41].  By contrast, other pathogens that cause 
chronic infections are thought of as being dependent on a distinct phagocyte, monocyte/macrophage 
following activation by T cells for their elimination [42].  Neutrophils are continuously produced 
by bone marrow and circulate in the blood until recruited to inflamed tissues through the cooperation 
of neutrophil surface adhesion molecules and endothelial cells as called by the term of neutrophil 
polarization and chemotaxis.  Most neutrophils die by apoptosis while still in circulation because of 
their short life span; apoptotic neutrophils are ingested by macrophages.  Neutrophils produce the 
enzyme-rich granules containing myeloperoxidase, elastase, and protease 3, aside from the 
respiratory burst being able to secrete reactive oxygen species (ROSs) by the NADPH oxidase 
system; ROSs are toxic to microorganisms [41].  These proteins and ROSs are also harmful to the 
cells and tissues of the host if released inappropriately [43].  In this context, neutrophils have been 
implicated as primary mediators of injury after reperfusion to coronary vascular endothelium and 
cardiomyocytes because neutrophils respond to myocardial ischemia-reperfusion in a manner similar 
to a bacterial invasion and ischemic stress-induced ROSs from activated neutrophils impart direct 
injury to endothelium and cardiomyocytes [44].
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Effects of volatile anesthetics on immune cells
Many in vitro investigations have elucidated the potential immunosuppressive effects of volatile 
anesthetics on various immune cells in a dose-dependent and time-dependent manner.
1) Neutrophil function
In the past, neutrophils were widely studied in the fields of anesthesiology, not only because 
these cells are important for the immune system, but also because this cell type is easy to study.  
More than two decades ago, Welch reported halothane-induced “reversible” inhibition of human 
neutrophil bacterial killing function in vitro [45].  The author suggested that the mechanism of 
inhibitory bacterial killing might be attributable to a deleterious effect of halothane on the oxidative 
microbicidal activity of human neutrophils.  The suggestion was examined and confirmed by other 
investigations, which indicated that the ROS production by activated neutrophils was inhibited by 
halothane, enflurane, isoflurane, and sevoflurane [46–47].  The mechanism by which volatile 
anesthetics inhibit the ROSs’ release from neutrophils is suggested to be either a direct inhibitory 
effect on NADPH oxidase or an inhibitory effect at some site in the signal transduction pathway 
regulating NADPH oxidase such as protein kinase C [47–48].  Inhibition of ROSs’ release by 
volatile anesthetics results in suppression of initial inflammatory responses through the reduced 
adherence of neutrophils to the endothelial cells because ROSs from neutrophils provide a stimulus 
for upregulation of endothelial adhesion molecules such as P-selectin and ICAM-1, which 
respectively mediate the initial rolling and slowing of neutrophils along the endothelial surface and 
the subsequent firm adherence of neutrophils to the endothelial cell surface [49–50].  Therefore, 
inhibitory effects of volatile anesthetics on neutrophil functions not only reduce the ability to kill 
microorganisms but also reduce the available information to initiate the inflammatory responses 
because tissue injury by activated neutrophils is a main source of “alarm” information that launches 
inflammation, which in turn launches immunity.
On the other hand, these inhibitory effects of volatile anesthetics on neutrophil functions might 
provide a therapeutically beneficial effect on ischemia-reperfusion injury.  Abundant evidence 
substantiates the role of neutrophils in ischemia-reperfused myocardium as a progenitor of primary 
inflammatory damage leading to reperfusion injuries, followed later by the extension of the infarcted 
zone and myocardial stunning, ultimately resulting in prolonged depression of post-ischemic 
contractile function [44].  The key elements that induce ischemia-reperfusion injury are ROSs that 
are released by neutrophils and adherence of neutrophils to the vascular endothelium via the 
adhesion molecules such as CD11b/CD18 and L-selectin on neutrophils and P-selectin and ICAM-1 
on endothelial cells [51].  Recent findings in various animal models and patients have suggested 
that isoflurane and sevoflurane might provide protective effects on ischemia-reperfusion injury by 
reducing both ROS production from neutrophils and postischemic adhesion of neutrophils to 
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endothelial cells [52].  These inhibitory actions of volatile anesthetics might be associated with the 
anesthetic preconditioning of the ischemic myocardium [53].
2) Monocyte and macrophage functions
Most in vivo and in vitro studies about the effects of volatile anesthetics on monocyte and 
macrophage functions are based on investigations into the functions of the alveolar macrophages.  
For example, halothane inhibits the intraalveolar recruitment of macrophages in response to 
influenza virus infection in mice [54].  Isoflurane decreases the phagocytotic capacity of human 
alveolar macrophages during surgery [55].  In vivo study using rat endotoxemia showed that 
inhalation of isoflurane reduced the release of proinflammatory cytokine, IL-1 in bronchoalveolar 
lavage fluid (BALF) [56].  This finding suggests the inhibitory effect of isoflurane on 
proinflammatory cytokine release from alveolar macrophages because the main source cells of 
proinflammatory cytokines in BALF in endotoxemia are alveolar macrophages.  In addition, the 
study demonstrated that inhalation of isoflurane increased the release of nitric oxide (NO) and 
expression of inducible nitric oxide synthase (iNOS) proteins from alveolar macrophages, which 
were completely inhibited by beta adrenoceptor antagonist propranolol. In this connection, 
Tschaikowsky et al. showed that the expression of iNOS by murine macrophage cell line was 
increased by volatile anesthetics (halothane, enflurane, isoflurane, and desflurane) when the cell line 
was stimulated with the combination of lipopolysaccharide (LPS) and IFN- [57].  Although the 
role of NO release from macrophages by volatile anesthetics remains unknown, NO might have 
several protective roles in the inflammatory response because NO-induced vasodilation might 
prevent accumulation of injurious mediators at the endothelium and might scavenge free radicals and 
prevent up-regulation of neutrophil CD11b/CD18 adhesion molecules [51, 58–59].  Indeed, the 
anti-inflammatory properties of volatile anesthetics in the endotoxin-challenged acute lung injury 
have been demonstrated previously [60–61].  In contrast, we also obtained conflicting results to 
those of previous studies using murine or rat macrophages, which indicated inhibited LPS-induced 
iNOS expression by volatile anesthetics (halothane, enflurane, isoflurane, and desflurane) [57] and 
NO release by isoflurane or sevoflurane [62–63]. Furthermore, no data in the literature describe the 
effects of volatile anesthetics on the antigen processing capacity or presenting by monocytes and 
macrophages (and dendritic cells) as APC.
3) NK cell function
The NK cells are of primary importance in the elimination of tumor target cells at the early 
stage of tumor development, up to and including tumor metastasis.  The decreased NK cell function 
during the perioperative period is associated with an increased risk of mortality in cancer patients [4, 
64–66].
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Many studies monitoring in vitro cell responses after surgery and anesthesia have reported 
decreased NK cell cytotoxic activity.  Two decades ago, Woods and Griffiths found that volatile 
anesthetics, halothane and enflurane, reversibly inhibited NK cell activity dose-dependently in vitro.  
One hour after removing the NK cells from exposure to the volatile anesthetics, full recovery of NK 
cell activity was apparent [67].  Halothane and isoflurane inhibit the augmentation of splenic NK 
cell cytotoxicity by interferon treatment in mice both in vivo and in vitro [68].  In addition, a study 
using an animal model indicated that halothane-induced suppression of NK cell activity increased 
tumor metastases in vivo [69].  Although the precise mechanism underlying the direct inhibitory 
effect of volatile anesthetics on NK cell activity remains unclear, volatile anesthetics might induce 
CD8＋T cells, which suppress activation of NK cell cytotoxicity, because in vitro depletion of CD8＋
T cells from splenocytes derived from anesthetized mice restored the ability of NK cells to respond 
to interferon stimulation [70].  In addition, perioperative depression of NK cell cytotoxicity might 
be associated with the activation of neuroendocrine system because changes in serum cortisol 
showed an inverse relationship with NK cell cytotoxicity during and after surgery [71].
4) Lymphocyte function
Various studies have shown inhibitory effects of volatile anesthetics on lymphocyte 
proliferation [72–77] and suppressive effects in cytokine releases in peripheral blood mononuclear 
cells (PBMC) [78–79].  Splenic T cells derived from rats anesthetized by 1% halothane for 5 h in 
vivo reduced the proliferative capacity and impaired their ability to express CD25 (IL-2) receptor in 
response to mitogens [77].  In vitro study using human PBMC demonstrated that exposure of 1% 
halothane for 60 min impaired both the immunoglobulins and concanavalin A-surface bindings to 
lymphocytes; this phenomenon was reversible after 24 h [76].  Exposure to halothane depressed the 
secretion of IFN- by human lymphocytes in response to a mitogen [78].  Other volatile anesthetics, 
sevoflurane, isoflurane, and enflurane also suppress the release of IL-1 and TNF-from human 
PBMC, including lymphocyte and NK cells, in response to tumor cells The inhibitory effects 
of volatile anesthetics on lymphocyte functions might reduce the immunocapacity against 
microorganisms and tumor cells. However, they might contribute to anti-inflammatory responses by 
regulating secretion of pro-inflammatory cytokines implicated in the pathophysiology of systemic 
inflammatory response syndrome (SIRS) [25].
Although the mechanisms by which volatile anesthetics inhibit the lymphocyte functions 
remain elusive, lymphocyte apoptosis induced by volatile anesthetics might be involved to some 
degree.  Isoflurane and sevoflurane directly induce apoptosis in human peripheral lymphocytes in 
vitro in a dose-dependent and time-dependent manner [80].  The induction of apoptosis is 
accompanied by the increased caspase-3-like activity in lymphocytes [80].  In accordance with the 
results, Loop et al. found that sevoflurane and isoflurane induce apoptosis in human T lymphocytes 
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dose-dependently through the apoptotic signaling pathway involving disruption of the mitochondrial 
membrane potential and release of cytochrome c from mitochondria to the cytosol [81].  The 
authors have surmised that cytochrome c released by the volatile anesthetics, the component of the 
electron transfer chain, engenders a failure to maintain the mitochondrial membrane potential and 
adenosine triphosphate (ATP) synthesis in lymphocytes, which results in caspase activation to induce 
apoptosis and cell death [82].  In addition, the decrease of mitochondrial transmembrane potential 
reportedly induces superoxides and other ROSs [83–84], which activate protein kinase C (PKC) and 
mitogen-activated activated protein kinases (MAPK) [85–86].  Loop et al. reported that sevoflurane 
inhibits activation of the transcription factor activator protein-1 (AP-1) in human T lymphocytes and 
that the suppression of AP-1 is associated with interference of the p38 MAPK cascade via increased 
phosphorylation of the p38 /p38isoforms[87]. Therefore, the decrease of mitochondrial 
transmembrane potential, the release of cytochrome c from mitochondria, and interference with the 
MAPK cascade might provide possible mechanisms for volatile anesthetics-induced inhibitory or 
anti-inflammatory effects on lymphocytes (Fig. 4).  In contrast to the toxic (apoptotic) or inhibitory 
effects of volatile anesthetics on the lymphocytes, volatile anesthetics impart a protective effect on 
the myocytes: anesthetic preconditioning in the ischemic heart [88].  Although this article does not 
specifically refer to anesthetic preconditioning, the mitochondrial membrane appears to play 
important roles in anesthetic preconditioning as well as the toxic (apoptotic) or inhibitory effects on 
the lymphocytes.  However, there might appear to be discrepancies in mitochondrial functions 
between myocytes and lymphocytes.  Briefly, as in lymphocytes, volatile anesthetics induce the 
attenuation of mitochondrial membrane potential in myocytes, which enhances the production of 
ROSs.  The enhanced production of ROSs leads to activation of PKC and p38 MAPK, which opens 
the mitochondrial adenosine triphosphate-sensitive K＋(KATP) channel in myocytes.  Consequences 
of mitochondrial KATP channel opening reduce cytosolic and mitochondrial calcium loading and 
improve myocardial oxygen efficiency during myocardial ischemia, which might lead to anesthetic 
preconditioning (Fig. 4).  Volatile anesthetic induced protection of mitochondria energetics in 
myocytes but not in lymphocytes would result in the reduction of cytochrome c release from 
mitochondria [89].  It might appear that the balance between the sarcoplasmic and mitochondrial 
KATP channels, the regulation of cytosolic Ca
2+, and/or NADH dehydrogenase activity which is a 
powerful generator of ROSs in cardiomyocytes, differ from those in lymphocytes.
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Effects of propofol on immune cells
Propofol, which belongs to the phenolic hydroxyl group, chemically resembles the antioxidant 
-tocopherol [90].  The accumulated data indicate that propofol has inhibitory effects on 
neutrophils and monocyte and macrophage functions of the innate immunity, but not on NK cells 
and lymphocytes functions.  These effects of propofol might be related in part to its lipid carrier 
vehicle [91].  Propofol appears to have anti-inflammatory and anti-oxidative actions through its 
inhibitory effects on innate immunity.
1) Neutrophil function
In vitro propofol dose-dependently inhibits 
N-formyl-methionyl-leucyl-phenylalanine-stimulated neutrophil chemotaxis  and ROS production 
[92]; it also impairs neutrophil phagocytosis of Escherichia coli and Staphylococcus aureus at 
clinically achievable concentrations [93, 94].  The reduction of the intracellular calcium 
concentration ([Ca]i) in neutrophils might be responsible for the functional inhibition by propofol 
[92].  However, other studies have found that propofol has no effect on phagocytosis of E. coli [95] 
or S. aureus [96] at clinically relevant concentrations.  Neutrophil polarization [97] and respiratory 
burst [91, 92] are reduced by clinical concentration of propofol in vitro.  Ex vivo human studies in 
critically ill patients indicated no remarkable effect on neutrophil respiratory burst [98].  Propofol 
decreases the release of IL-8 from lipopolysaccharide (LPS)-stimulated neutrophils, although 
intracellular IL-8 and mRNA levels remain increased [99].  That fact suggests that the decrease of 
IL-8 release by propofol occurs at the post-translational level without altering mRNA.  In another 
study, of intracellular signaling molecules, propofol inhibited phosphorylation of p42 MAPK in 
neutrophils [100].  This finding might explain the inhibitory effects of propofol on neutrophil 
functions.
2) Monocyte and macrophage functions
Propofol has been shown to impair monocyte and macrophage functions, including chemotaxis 
[101, 102], oxidative burst [93, 102], and phagocytosis [93, 102].  The suppressive effects of 
propofol on murine macrophage chemotaxis and oxidative burst are reversed 6–24 h after the 
removal of propofol [102].  In addition, LPS-induced expression of IFN- mRNA in murine 
macrophages is blocked by propofol [102].  The reduction of the membrane potential of 
macrophage mitochondria and ATP synthesis in macrophages might be responsible for 
propofol-induced inhibitory effects on macrophages [101, 102].  Exposure of murine macrophages 
to propofol at a low concentration (3–30 M) did not affect cell viability. However, a high 
concentration (300M) of propofol would cause arrest of the cell cycle in G1/S phase, increase 
lactate dehydrogenase release and lead to cell death [102].  In contrast to the cell death-induction of 
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macrophages by a high concentration of propofol, another study demonstrated that propofol (30 M) 
protects murine macrophages from NO-induced apoptosis as well as cell death [103].  In addition, 
propofol suppresses NO biosynthesis by inhibiting iNOS expression in LPS-activated murine and 
human macrophages at a clinically relevant concentration [104,105].  The production of 
proinflammatory cytokines, TNF-, IL-and IL-6 in LPS-activated human macrophages are 
inhibited by propofol at a pre-translational level [105].  However, conflicting data have been 
reported related to whether or not propofol directly stimulates human monocytes to release TNF and 
IL-1 [106].
3) NK cell function
Little information is available related to the effects of propofol on NK cell function in vivo and 
in vitro.  Results of an in vivo animal study suggest that propofol has no effects on NK cell activity 
of whole blood and on the susceptibility to tumor metastasis in nonoperated rats after anesthesia [69].  
Results of an in vivo human study showed a remarkable decrease of circulating NK cell number in 
patients anesthetized with propofol and fentanyl after induction of anesthesia [107].
4) Lymphocyte function
Propofol has no effect on in vitro lymphocyte proliferation from healthy volunteers [108, 109]. 
Nevertheless, in surgical intensive care patients, it apparently inhibits lymphocyte proliferation in 
response to pokeweed mitogen [108].  This result suggests that B lymphocyte proliferation in 
critically ill patients might be inhibited by propofol.  In vitro T lymphocyte proliferation in 
response to phytohaemagglutinin is unaffected in healthy volunteers [109].  Furthermore, the 
Th1/Th2 ratio, as measured by IFN-(produced by Th1 cells) and IL-4 (produced by Th2 cells) 
accumulation in human PBMC, is increased by propofol [110].  The cytokines produced by Th1 
cells activate cells involved in cell-mediated immunity such as NK cells, monocytes and 
macrophages, and CD8＋cytotoxic T cells.  In contrast, the cytokines produced by Th2 cells trigger 
B cells to synthesize immunoglobulins.  Therefore, the increased Th1/Th2 ratio by propofol, which 
is contributing to the maintenance of cell-mediated immunity, might be beneficial for 
immunocompromised patients.  Propofol does not induce lymphocyte apoptosis in human in 
clinically acceptable concentrations (1–10 g/ml) but not in high concentration (50 g/ml) [111].  
In this context, K＋channels might be associated with the induction of apoptosis at a high dose of 
propofol because propofol blocks voltage-gated K＋channels in human T lymphocytes [112].  In 
addition, results of a recent study investigating the activation of human T lymphocytes suggest that 
propofol does not inhibit the activation of nuclear factor kappa B (NK-a transcription factor 
involved in the expression of many genes including IFN-IL-2, IL-6, and IL-8 [113].  This finding 
is in accordance with a previous report indicating that propofol does not impair cytokine release in 
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response to endotoxin in a whole blood culture medium from healthy volunteers [114].  
Collectively, propofol appears to impart only minor effects on lymphocyte functions at clinically 
relevant concentrations.
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Effects of opioids on immune cells
The immunosuppressive effects of opioids have been known for more than a century.  
Although the precise mechanisms remain unidentified, opioid-induced immunomodulations are 
mediated by opioid receptors [115] and by the participation of both the autonomic nervous system 
[116] and the hypothalamic-pituitary-adrenal axis (HPA) [117].  The activation of opioid receptors 
can regulate the peripheral immune system throughout the stimulation of HPA [117] and the 
sympathetic nervous system [116].  The activation of opioid receptors in HPA elicits the production 
of ACTH from the pituitary, which in turn elicits the release of glucocorticoids, which suppress the 
immune system [117, 118].  Activation of the sympathetic nervous system by opioids elicits the 
release of catecholamines, which have been demonstrated to suppress lymphocyte, NK cell, and 
macrophage functions [119].  Four major classes of opioid receptors have been identified: 
and .  These opioid receptors are present not only in nervous system, including HPA, but 
also in immunocompetent cells.  Neutrophils and NK cells express and receptors, and 
monocytes and macrophages and T cells are expressing , and receptors [120].  A classical 
opioid receptor is thought to be involved in morphine-related immunomodulations because the 
effects of morphine can be blocked by the antagonist naloxone [121].
Morphine stimulates 3 receptors on immune cells to increase intracellular calcium transients 
([Ca]i), which might in turn activate constitutive nitric oxide synthase (cNOS) liberating NO.  The 
NO in turn stabilizes IBby preventing its degradation and inhibits nuclear factor (NF)-B binding 
to the representative DNA promoter region and subsequent expressions of the proinflammatory 
cytokines and adhesion molecules, resulting in anti-inflammation [122].
Morphine suppresses neutrophil functions such as phagocytosis, respiratory burst, and 
complement receptors expression by stimulating NO release via 3 receptors [123].  The inhibitory 
production of ROSs through the respiratory burst by neutrophils is reversible by naloxone.  In vivo
studies demonstrate that morphine inhibits the proliferation and differentiation of macrophage 
progenitor cells [124], phagocytosis by monocytes and macrophages [125], and IL-10 and IL-12 
production from monocytes and macrophages [121].  These impairments were evident with 
peritoneal, alveolar and splenic macrophages, indicating a general down-regulation of innate 
immunity.  It appears from results of all these studies that morphine acts to decrease host defenses 
against various infectious diseases.
Furthermore, NK cell is very sensitive to morphine-induced modulation in vivo.  In vivo
administration of morphine depresses NK cell activity [126].
The T lymphocyte functions and B lymphocyte functions are also suppressed by morphine in 
vivo.  The mitogenic response [127] and induction of antibody-forming by B lymphocytes [121] are 
suppressed by morphine administration in vivo.  Moreover, T lymphocyte proliferation is decreased 
by both acute and chronic morphine administrations [125, 128].  Production of IFN- and IL-2 (i.e.
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Th1 cytokines) by T lymphocytes is inhibited by morphine in vivo [121].  However, the results 
reported of morphine modulation of IL-4 production (i.e. Th2 cytokine) are contradictory.  In vivo
administration of morphine increased IL-4 production by T lymphocytes in one experiment [129] 
and decreased it in another experiment [130].  In addition, an interesting study demonstrated that 
morphine can trigger T lymphocyte apoptosis by modulating the Fas-Fas ligand system in vitro; this 
effect is also mediated by opioid receptors present on immune cells themselves [131].
In contrast to the morphine-induced inhibitory effects on immune cells, synthetic opioids such 
as fentanyl and remifentanil seem to have no effect to attenuate immune cell responses through 
reduced interaction of synthetic opioids with specific opioid receptors.  Fentanyl, remifentanil, and 
alfentanil do not impair the function of neutrophils such as respiratory burst [132] and phagocytosis 
[133].  Indeed, fentanyl has no effects on cytokine releases from whole blood cells [114].  
Although one experiment using an animal model indicated that a relative high dose of fentanyl 
suppresses NK activity and resistance to tumor metastases [134], the clinical relevant dose of 
fentanyl augments NK activity and increases the number of NK cells and CD8＋cytotoxic T 
lymphocytes in healthy volunteers [135].  On the other hand, the quantities of circulating B and T 
lymphocytes remain unchanged [136].  Fentanyl has no ability to bind to 3 receptors. Therefore, it 
does not influence NO release and cellular adhesion [137].  As a result, fentanyl appears to lack the 
ability to downregulate the inflammatory responses associated with surgery.
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Effects of local anesthetics on immune cells
In surgical patients, extradural anesthesia with local anesthetics reduces the activation of the 
neuroendocrine system and then prevents immunosuppression during surgery.  In patients 
undergoing hysterectomy, the depression of NK cell cytotoxic activity in patients receiving general 
anesthesia was abrogated when patients received both general and extradural anesthesia.  The 
inhibitory effect on the depression of NK cell activity was associated with the suppression of cortisol 
response [138].  In patients undergoing total hip replacement, cortisol levels were lower during 
surgery in the regional anesthesia group than in the general anesthesia group [139].  These results 
imply that surgery-related increases in serum cortisol are attenuated by extradural analgesia.  
Therefore, it is clear that afferent neural blockade by extradural anesthesia can decrease the 
intra-operative and post-operative neuroendocrine stress responses [140].  Such decreased 
lymphocyte proliferation and lymphokine production in patients under general anesthesia were not 
seen in patients undergoing extradural anesthesia [141].  In addition, spinal anesthesia prevented 
the depressed mitogen-induced lymphocyte proliferation in patients undergoing general anesthesia 
for prostate surgery [142].  Recently, in vivo experiments using a murine model revealed that the 
addition of spinal block to sevoflurane-general anesthesia accompanying laparotomy attenuates the 
suppression of tumoricidal function of liver mononuclear cells by preserving Th1/Th2 cytokine 
balance and NK cell/NK-T cell functions, resulting in the reduction of tumor metastases [143].  
These effects of extradural or spinal anesthesia on immunosuppression by surgery and general 
anesthesia might protect patients from post-operative development of infectious complications or 
tumor metastases [144].
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Implications of in vivo studies comparing anesthetic-induced immunomodulation between 
volatile and intravenous anesthetics
The accumulated evidence described above suggests that immunocompetent cells seem to be 
more sensitive to volatile anesthetics than to propofol or synthetic opioids because propofol and 
synthetic opioids have less effect on immunocompetent cells.  In addition, attenuation of stress 
responses by the combination of the extradural anesthesia with general anesthesia protects surgical 
patients from further immunosuppression during the perioperative periods.  In this context, a 
general anesthesia using propofol and fentanyl with epidural/spinal anesthesia might be optimal for 
immunocompromised hosts to prevent tumor metastases or postoperative nosocomial infections, and 
the general anesthesia using volatile anesthetics might be useful for patients with 
ischemia/reperfusion injury involving cardiopulmonary bypass or SIRS.  Indeed, in vivo studies 
comparing perioperative immunomodulation between inhalation anesthesia and intravenous 
anesthesia have indicated more suppressive effects of inhalation anesthesia on the immune system 
than those of total intravenous anesthesia (TIVA).  The number of T lymphocytes and expression of 
HLA-DR decrease more in response to surgery after inhalation anesthesia when compared with 
TIVA [145].  The plasma level of IL-6, which is important to stimulate the neuroendocrine system, 
significantly increases during and after abdominal surgery with inhalation anesthesia [146].  A 
lower level of serum cortisol has been reported in patients undergoing TIVA compared to isoflurane 
anesthesia [146, 147].  Isoflurane anesthesia reduces the bactericidal activity of macrophages more 
effectively than does propofol anesthesia [148].  In addition, the Th1/Th2 ratio decreases 
significantly after isoflurane anesthesia, but it does not change after propofol anesthesia [149].
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Conclusion
The perioperative period is crucial for long-term prognosis of surgical patients because the 
direct immunomodulatory effects of anesthetics are a double-edged sword: immunosuppression 
might be both beneficial and harmful.  Unfortunately, insufficient attention to long-term prognosis 
has been directed to the perioperative period, even by anesthesiologists.  The negative 
consequences associated with perioperative immunosuppression, such as an increased risk of tumor 
metastasis and postoperative infections, might be decreased by the optimal selection of anesthetics 
and anesthetic techniques.  In contrast, anti-inflammatory effects of anesthetics might be 
therapeutically beneficial in some situations such as ischemia and reperfusion injury and SIRS.  In 
the future, it will become necessary to differentiate the different applications of anesthetics with 
careful regard to the immunological status of the surgical patients.
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Figure Legends
Fig. 1.  Neuro-immune-endocrine interactions during surgical stress.  The 
hypothalamic-pituitary-adrenal axis (HPA), sympathetic nervous system (SNS), and cytokines 
represent the peripheral limbs of the stress system.  The central components of this system are 
located in the hypothalamus and the brain stem.  Proinflammatory cytokines such as TNF-, 
IL-1,and IL-6 released from surgical stress-activated immune cells stimulate the 
corticotrophin-releasing hormone (CRH) and activate both the HPA and SNS.  Catecholamines and 
glucocorticoids derived from the HPA and SNS drive a Th2 shift at the level of both 
antigen-presenting cells (APC) and helper T cells to produce anti-inflammatory cytokines such as 
IL-4 and IL-10.  These anti-inflammatory cytokines suppress cell-mediated immune responses, 
resulting in immunosuppression.  Solid lines represent stimulation; dashed lines represent 
inhibition.
Fig. 2.  Scheme showing possible modulators of immune competence during anesthesia and surgery.  
Anesthetics impart direct effects on the immune system.
Fig. 3.  Interactions between NK cells, Th cells, Tc cells, and APC in anti-tumor immunity.  
Particularly, NK cells function not only as a surveillant in the early stage of tumor development but 
also as a helper in priming process of APC, tumor-specific Tc cells and Th1 cells by producing 
IFN-NK cells, natural killer cells; Th cells, helper T cells; Tc cells, cytotoxic T cells; APC, 
antigen-presenting cells; and MHC, major histocompatibility complex.

Fig. 4. Possible pathways leading to volatile anesthetic-induced apoptosis and anti-inflammatory 
responses in lymphocytes and the preconditioning in cardiac myocytes.  The key and shared 
element of the volatile anesthetic-induced modulations of cellular functions is the attenuation of 
mitochondrial membrane potential:  m, inner mitochondrial membrane potential; ETC, electron 
transport chain; ROSs, reactive oxygen species; mKATP, mitochondrial adenosine triphosphate 
sensitive K＋channel; PKC, protein kinase C; MAPK, mitogen activated protein kinases; and AP-1, 
activator protein-1.
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